Veterans’ Support Amendment Regulations (No 2) 2022
2022/80
Veterans’ Support Amendment Regulations (No 2) 2022
Cindy Kiro, Governor-General
Order in Council
At Wellington this 21st day of March 2022
Present:
Her Excellency the Governor-General in Council
These regulations are made under section 265 of the Veterans’ Support Act 2014—
(a)
on the advice and with the consent of the Executive Council; and
(b)
on the recommendation of the Minister for Veterans made in accordance with section 23 of that Act.
Regulations
1 Title
These regulations are the Veterans’ Support Amendment Regulations (No 2) 2022.
2 Commencement
These regulations come into force on 22 April 2022.
3 Principal regulations
These regulations amend the Veterans’ Support Regulations 2014.
4 Schedule 1 amended
Amend Schedule 1 as set out in Schedule 1 of these regulations.
5 Schedule 2A amended
Amend Schedule 2A as set out in Schedule 2 of these regulations.
Schedule 1 Schedule 1 amended
In the item relating to aortic stenosis,—
(a)
replace “21/2013”
with “13/2022”
; and
(b)
replace “22/2013”
with “14/2022”
.
In the item relating to chronic solvent encephalopathy,—
(a)
replace “chronic solvent encephalopathy”
with “chronic solvent-induced neurocognitive disorder”
; and
(b)
replace “71/2013”
with “109/2021”
; and
(c)
replace “72/2013”
with “110/2021”
.
In the item relating to colorectal adenoma,—
(a)
replace “35/2013”
with “15/2022”
; and
(b)
replace “36/2013”
with “16/2022”
.
After the item relating to Gaucher’s disease, insert:
| gender dysphoria | 113/2021 | 114/2021 |
In the item relating to gingivitis,—
(a)
replace “45/2013”
with “17/2022”
; and
(b)
replace “46/2013”
with “18/2022”
.
In the item relating to goitre,—
(a)
replace “23/2013”
with “9/2022”
; and
(b)
replace “24/2013”
with “10/2022”
.
In the item relating to Graves’ disease,—
(a)
replace “Graves’ disease”
with “Graves disease”
; and
(b)
replace “33/2013”
with “7/2022”
; and
(c)
replace “34/2013”
with “8/2022”
.
In the item relating to Hashimoto’s thyroiditis,—
(a)
replace “Hashimoto’s thyroiditis”
with “Hashimoto thyroiditis”
; and
(b)
replace “31/2013”
with “1/2022”
; and
(c)
replace “32/2013”
with “2/2022”
.
In the item relating to hyperthyroidism and thyrotoxicosis,—
(a)
replace “27/2013”
with “5/2022”
; and
(b)
replace “28/2013”
with “6/2022”
.
In the item relating to hypothyroidism,—
(a)
replace “29/2013”
with “3/2022”
; and
(b)
replace “30/2013”
with “4/2022”
.
In the item relating to malignant neoplasm of the colorectum,—
(a)
replace “malignant neoplasm of the colorectum”
with “malignant neoplasm of the colon and rectum”
; and
(b)
replace “37/2013”
with “19/2022”
; and
(c)
replace “38/2013”
with “20/2022”
.
In the item relating to motor neurone disease,—
(a)
replace “67/2013”
with “111/2021”
; and
(b)
replace “68/2013”
with “112/2021”
.
In the item relating to narcolepsy,—
(a)
replace “7/2014”
with “11/2022”
; and
(b)
replace “8/2014”
with “12/2022”
.
Schedule 2 Schedule 2A amended
Replace the item relating to chronic solvent encephalopathy with:
| chronic solvent-induced neurocognitive disorder |
Replace the item relating to Graves’ disease with:
| Graves disease |
Replace the item relating to Hashimoto’s thyroiditis with:
| Hashimoto thyroiditis |
Replace the item relating to malignant neoplasm of the colorectum with:
| malignant neoplasm of the colon and rectum |
Michael Webster,
Clerk of the Executive Council.
Explanatory note
This note is not part of the regulations, but is intended to indicate their general effect.
These regulations, which come into force on 22 April 2022, amend the Veterans’ Support Regulations 2014 (the principal regulations).
Regulation 4 and Schedule 1 amend Schedule 1 of the principal regulations, which lists the Australian statements of principles (the statements) that apply to specified medical conditions for the purposes of the Veterans’ Support Act 2014 (the Act). The amendments—
replace the names of 4 conditions in order to reflect the statements (the new names are chronic solvent-induced neurocognitive disorder, Graves disease, Hashimoto thyroiditis, and malignant neoplasm of the colon and rectum):
update references to the statements for the above-mentioned conditions and for 8 other conditions (aortic stenosis, colorectal adenoma, gingivitis, goitre, hyperthyroidism and thyrotoxicosis, hypothyroidism, motor neurone disease, and narcolepsy):
insert the name of a new condition (gender dysphoria) and references to 2 new statements related to that condition.
Regulation 5 and Schedule 2 amend Schedule 2A of the principal regulations, which lists accepted late-onset conditions for the purposes of the definition of accepted late-onset condition in section 7 of the Act. The amendments replace the names of 4 accepted late-onset conditions with their new names (chronic solvent-induced neurocognitive disorder, Graves disease, Hashimoto thyroiditis, and malignant neoplasm of the colon and rectum).
Date of notification in Gazette: 24 March 2022.
These regulations are administered by the New Zealand Defence Force.